DE69835534T3 - Wirkstoffkombination aus cpy2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung - Google Patents

Wirkstoffkombination aus cpy2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung Download PDF

Info

Publication number
DE69835534T3
DE69835534T3 DE69835534T DE69835534T DE69835534T3 DE 69835534 T3 DE69835534 T3 DE 69835534T3 DE 69835534 T DE69835534 T DE 69835534T DE 69835534 T DE69835534 T DE 69835534T DE 69835534 T3 DE69835534 T3 DE 69835534T3
Authority
DE
Germany
Prior art keywords
cyp2a6
nicotine
individual
smoking
tobacco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835534T
Other languages
German (de)
English (en)
Other versions
DE69835534T2 (de
DE69835534D1 (de
Inventor
M. Edward Toronto SELLERS
F. Rachel Toronto TYNDALE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicogen Inc
Original Assignee
Nicogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27490603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69835534(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicogen Inc filed Critical Nicogen Inc
Application granted granted Critical
Publication of DE69835534D1 publication Critical patent/DE69835534D1/de
Publication of DE69835534T2 publication Critical patent/DE69835534T2/de
Publication of DE69835534T3 publication Critical patent/DE69835534T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69835534T 1997-12-01 1998-12-01 Wirkstoffkombination aus cpy2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung Expired - Lifetime DE69835534T3 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US6702197P 1997-12-01 1997-12-01
US6702097P 1997-12-01 1997-12-01
US67020P 1997-12-01
US67021P 1997-12-01
US8484798P 1998-05-08 1998-05-08
US84847P 1998-05-08
US10739298P 1998-11-06 1998-11-06
US107392P 1998-11-06
PCT/CA1998/001093 WO1999027919A2 (en) 1997-07-17 1998-12-01 Cyp2a enzymes and their use in therapeutic and diagnostic methods

Publications (3)

Publication Number Publication Date
DE69835534D1 DE69835534D1 (de) 2006-09-21
DE69835534T2 DE69835534T2 (de) 2007-08-09
DE69835534T3 true DE69835534T3 (de) 2010-09-23

Family

ID=27490603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835534T Expired - Lifetime DE69835534T3 (de) 1997-12-01 1998-12-01 Wirkstoffkombination aus cpy2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung

Country Status (12)

Country Link
EP (1) EP1033979B2 (enExample)
JP (1) JP2001524516A (enExample)
CN (1) CN100362995C (enExample)
AT (1) ATE335484T1 (enExample)
AU (1) AU762671C (enExample)
BR (1) BR9815128A (enExample)
CA (1) CA2312851A1 (enExample)
DE (1) DE69835534T3 (enExample)
ES (1) ES2273441T5 (enExample)
NZ (1) NZ505439A (enExample)
PT (1) PT1033979E (enExample)
WO (1) WO1999027919A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207924A1 (de) 2016-02-17 2017-08-23 Flaxan GmbH & Co. KG Pharmazeutische zubereitung zur hemmung humaner cyp-enzyme

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900490D0 (sv) * 1999-02-15 1999-02-15 A & Science Invest Ab Diagnostic agent and method
GB9927806D0 (en) * 1999-11-24 2000-01-26 Isis Innovation Genetic indicators of tobacco consumption
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
CN1308462C (zh) * 2003-09-22 2007-04-04 周宏灏 个体化用药基因型诊断芯片及其制造方法和应用方法
KR100829122B1 (ko) * 2006-12-05 2008-05-13 한국과학기술연구원 당귀 추출물 또는 이로부터 분리한 쿠마린계 화합물을 유효성분으로 함유하는 폐암 예방용 조성물
EP2031072A1 (en) * 2007-08-27 2009-03-04 Andreas Ziegler Method for in-vitro diagnosing a predisposition to smoking and a pharmaceutical composition for treating tobacco abuse
JP5275060B2 (ja) * 2009-01-30 2013-08-28 学校法人近畿大学 Ｃｙｐ２ａ６阻害剤及びｃｙｐ２ａ６阻害活性物質のスクリーニング方法
CN104004852B (zh) * 2014-06-17 2015-12-02 陕西佰美基因股份有限公司 一种基于荧光定量pcr检测cyp2a6全基因缺失的方法
EP3157519B1 (en) * 2014-06-19 2021-05-12 Immunolight, LLC Methods and systems for treating cell proliferation disorders with psoralen derivatives
CN116183779B (zh) * 2023-04-18 2025-01-24 云南省烟草农业科学研究院 基于一步净化和液相色谱-串联质谱的烟气中TSNAs测定方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066998C1 (ru) * 1992-06-25 1996-09-27 Валерий Иванович Вольвич Способ получения средства для лечения вирусного гепатита а
GB2303853B (en) * 1994-06-16 1998-12-23 Us Health Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes
DE19646977A1 (de) * 1995-09-29 1998-01-15 Schwabe Willmar Gmbh & Co Stabiler Extrakt aus Hypericum perforatum L., Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen
AU742628B2 (en) † 1996-07-17 2002-01-10 Nicogen Inc. Methods for regulating nicotine metabolism

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207924A1 (de) 2016-02-17 2017-08-23 Flaxan GmbH & Co. KG Pharmazeutische zubereitung zur hemmung humaner cyp-enzyme

Also Published As

Publication number Publication date
CA2312851A1 (en) 1999-06-10
AU1328699A (en) 1999-06-16
CN100362995C (zh) 2008-01-23
AU762671B2 (en) 2003-07-03
DE69835534T2 (de) 2007-08-09
WO1999027919A2 (en) 1999-06-10
NZ505439A (en) 2005-02-25
ES2273441T5 (es) 2010-06-28
EP1033979B9 (en) 2007-02-28
JP2001524516A (ja) 2001-12-04
DE69835534D1 (de) 2006-09-21
ES2273441T3 (es) 2007-05-01
EP1033979A2 (en) 2000-09-13
EP1033979B1 (en) 2006-08-09
WO1999027919A3 (en) 1999-08-12
BR9815128A (pt) 2000-10-10
EP1033979B2 (en) 2010-02-24
AU762671C (en) 2004-11-18
CN1299276A (zh) 2001-06-13
ATE335484T1 (de) 2006-09-15
PT1033979E (pt) 2006-12-29

Similar Documents

Publication Publication Date Title
DE69434794T2 (de) Kombination von dextromethorphan mit quinidine oder quinine sulfat zur behandlung verschiedener refraktärer störungen
US7371414B2 (en) Therapeutic and diagnostic methods dependent on CYP2A enzymes
DE69835534T3 (de) Wirkstoffkombination aus cpy2a enzyme inhibitoren und nikotine und ihre therapeutische anwendung
TW201505634A (zh) 藥物戒斷之無毒治療方法
JP2001515475A (ja) 尿失禁、動揺病及びめまいの治療薬の製造のためのデスカルボエトキシロラタジンの使用
US20050032844A1 (en) Methods for regulating nicotine metabolism
Dupont et al. Oxatomide in the treatment of pruritus senilis: a double-blind placebo-controlled trial
US20080319025A1 (en) Therapeutic and Diagnostic Methods Dependent on CYP2A Enzymes
AU742628B2 (en) Methods for regulating nicotine metabolism
Oliveto et al. Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure
WO2005123053A2 (en) Use of cb2 receptors agonists for the treatment of huntington’s disease
AU2003268826A1 (en) CYP2A enzymes and their use in therapeutic and diagnostic methods
MXPA00005446A (en) Therapeutic and diagnostic methods dependent on cyp2a enzymes
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
Benlhabib Alternative treatment for alcohol-dependence in alcohol preferring (P) rats
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物
CN114786677A (zh) 用于治疗物质使用障碍的18-mc
HK40073320A (en) 18-mc for treatment of substance use disorders
Calvey et al. Proceeding of the British Pharmacological Society, Clinical Pharmacology Section, 16‐18th December, 1980, University of London. Abstracts.
PERUCCA et al. Britbsh Pharmacoloqical
CA2227403A1 (en) Oral nicotine composition and methods
HK1140378B (en) Compositions and methods for prophylaxis and treatment of addictions
HK1140378A (en) Compositions and methods for prophylaxis and treatment of addictions

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE ISENBRUCK BOESL HOERSCHLER WICHMANN